[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-disorder":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,53,90,118,145,174,207,235,266,295,321,346,376,400,453,483,505,532,556,583,609,640,668,690,715],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100648849","digital-dietary-intervention-for-patients-receiving-glp-1-receptor-agonist-therapy-100648849",false,"NCT07728669","Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy","Efficacy of a Digital Dietary Intervention (NutriSteppe Application) in Improving Metabolic Parameters in Adults With Type 2 Diabetes Mellitus, Obesity or Overweight With Comorbidities Who Are Receiving GLP-1 Receptor Agonist Therapy and Other Medications Prescribed Under Routine Clinical Protocols","NutriSteppe","Inclusion Criteria:\n\n* Age 21-65 years inclusive at the time of signing informed consent.\n* Male or female.\n* Overweight with at least one comorbidity, including diabetes mellitus; arterial hypertension of at least 130\u002F85 mmHg or use of antihypertensive medication; dyslipidemia defined as triglycerides of at least 1.7 mmol\u002FL, reduced HDL cholesterol below 1.0 mmol\u002FL in men or below 1.3 mmol\u002FL in women, or use of lipid-lowering medication; cardiovascular disease; respiratory or joint disease; non-alcoholic fatty liver disease; sleep disorders; or other comorbidities.\n* For participants with overweight: body mass index of 25.0-29.9 kg\u002Fm² for the Caucasian population or 23.0-27.4 kg\u002Fm² for the Asian population, together with abdominal obesity defined as waist circumference of at least 94 cm in men and 80 cm in women of the European population, or at least 90 cm in men and 80 cm in women of the Asian population.\n* Class I-III obesity where diet combined with physical activity has been ineffective, defined as weight loss of less than 5% over 3 months.\n* Class I obesity: body mass index of 30.0-34.9 kg\u002Fm² for the Caucasian population or 27.5-32.4 kg\u002Fm² for the Asian population.\n* Class II obesity: body mass index of 35.0-39.9 kg\u002Fm² for the Caucasian population or 32.5-37.4 kg\u002Fm² for the Asian population.\n* Type 2 diabetes mellitus with HbA1c of at least 6.5% (48 mmol\u002Fmol), fasting glucose of at least 6.1 mmol\u002FL in capillary whole blood or at least 7.0 mmol\u002FL in venous plasma, glucose of at least 11.1 mmol\u002FL two hours after an oral glucose tolerance test, or random glucose of at least 11.1 mmol\u002FL.\n* Body mass index of at least 25 kg\u002Fm² and no more than 40 kg\u002Fm² at screening.\n* Already receiving, or prescribed, GLP-1 receptor agonist therapy with semaglutide by the treating physician independently of the study. The study does not prescribe or modify this therapy.\n* Stable doses of medications for chronic conditions, including antihypertensive agents and statins, for at least 8 weeks before screening.\n* Ownership of an iOS or Android smartphone with internet access and willingness to download and use the \"NutriSteppe\" application if assigned to the intervention group.\n* Ability and willingness to provide written informed consent and comply with study procedures.\n* Women of childbearing potential must use effective contraception throughout the study.\n\nExclusion Criteria:\n\n* Diagnosis of type 1 diabetes mellitus.\n* History of diabetic ketoacidosis or hyperglycemic hyperosmolar state.\n* Initiation of GLP-1 receptor agonist therapy less than 4 weeks before screening.\n* Current insulin therapy.\n* Personal or family history of medullary thyroid carcinoma.\n* Personal history of multiple endocrine neoplasia type 2 (MEN2).\n* History of acute or chronic pancreatitis.\n* Active gallbladder disease or history of gallbladder disease within 6 months before screening.\n* Severe gastrointestinal disease, including gastroparesis.\n* Major cardiovascular event within 6 months before screening, including myocardial infarction, stroke, transient ischemic attack, unstable angina, coronary artery bypass grafting, or percutaneous coronary intervention.\n* Uncontrolled arterial hypertension, defined as systolic blood pressure above 160 mmHg or diastolic blood pressure above 100 mmHg at screening.\n* Chronic kidney disease with an estimated glomerular filtration rate below 30 mL\u002Fmin\u002F1.73 m² using the MDRD or CKD-EPI formula.\n* Severe hepatic impairment classified as Child-Pugh class C, or ALT or AST greater than three times the upper limit of normal.\n* Active malignancy or history of malignancy within 5 years, except successfully treated basal cell or squamous cell carcinoma of the skin.\n* Established HIV infection, active hepatitis B defined as HBsAg positive with detectable HBV DNA, or hepatitis C virus infection.\n* History of bariatric surgery or bariatric surgery planned during the study.\n* Anorexia nervosa, bulimia nervosa, or binge eating disorder diagnosed or active within the past year.\n* Pregnancy or breastfeeding.\n* Planning pregnancy during the study.\n* Woman of childbearing potential unwilling to use effective contraception.\n* Use of weight-loss medication, including orlistat, phentermine, combinations with topiramate, naltrexone-bupropion, or other weight-loss medication within 3 months before screening.\n* Use of systemic corticosteroids, excluding inhaled or topical corticosteroids, for more than 2 weeks within 3 months before screening.\n* Use of antipsychotic medication associated with significant weight gain unless used at a stable dose for more than 6 months.\n* Participation in another interventional clinical study within 30 days before screening.\n* Known hypersensitivity to semaglutide or any excipient.\n* No smartphone or unwillingness to use digital health technology.\n* Severe mental disorder impairing the ability to provide informed consent or comply with the protocol.\n* Active alcohol or drug dependence within the past year.\n* Any condition that, in the investigator's opinion, may compromise participant safety or the integrity of the study.","ALL","21 Years","65 Years",{"count":22,"type":23},120,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to learn whether adding the NutriSteppe digital dietary intervention to routine medical care improves metabolic health in adults aged 21 to 65 years with type 2 diabetes mellitus, obesity, or overweight with related health conditions. Participants are already receiving or have been prescribed glucagon-like peptide-1 (GLP-1) receptor agonist therapy by their treating physicians outside the study.\n\nThe main question is:\n\nDoes the NutriSteppe digital dietary intervention improve glycated hemoglobin (HbA1c), a measure of average blood glucose, after 12 weeks compared with routine medical care alone?\n\nThe study will also assess changes in fasting blood glucose, body weight, body mass index, waist circumference, cholesterol, triglycerides, blood pressure, diet quality, quality of life, dietary adherence, and safety.\n\nResearchers will randomly assign participants to one of two groups. The control group will continue routine medical care and receive general lifestyle advice. The intervention group will continue routine medical care and use the NutriSteppe application for 12 weeks to receive personalized dietary support.\n\nParticipants in both groups will:\n\n* Attend study visits and complete the examinations, laboratory tests, and questionnaires specified in the study protocol.\n* Photograph everything they eat and drink.\n* Have their food photographs automatically analyzed using Tagam-AI, a system developed for this study.\n* Be able to view the results of the food photograph analysis.\n\nThe photography and automated analysis procedures will be the same in both groups. Only participants in the intervention group will receive personalized dietary recommendations generated from these data through the NutriSteppe application.",[29,30,31,32],"Type 2 Diabetes Mellitus (T2DM)","Obesity (Disorder)","Overweight","Metabolic Syndrome",[16,34,35,36,37,38,39],"Digital Dietary Intervention","Personalized Nutrition","GLP-1 Receptor Agonist","Semaglutide","Glycated Hemoglobin","HbA1c","RECRUITING","2026-08-10",{"date":43,"type":44},"2026-08-11","ACTUAL",{"date":46,"type":44},"2026-07-20",{"date":48,"type":23},"2027-01",{"name":50,"class":51},"Kazakh Academy of Nutrition","OTHER",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100651355","i-opera-a-european-study-testing-a-new-way-to-do-health-research-100651355","NCT07759544","I-OPERA: A European Study Testing a New Way to Do Health Research.","The I-OPERA Study: IQVIA Obesity Pilot in Europe to Test a New Patient-centric Research Approach","I-OPERA","Inclusion Criteria:\n\n* Age ≥18 years\n* Resident in England, France, or Germany\n* Self-reported height and weight corresponding to a calculated BMI ≥27 kg\u002Fm²\n\nExclusion Criteria:\n\n* Unable to provide electronic informed consent form (ICF)\n* Unable to name at least one HCP involved in their care and the affiliated institution, where applicable\n* Unwilling to authorise medical records access via DSAR (where applicable) or direct upload\n* Unable to complete online surveys (approximately 30 minutes) on own device (computer, smartphone, or tablet)\n* Participants whose HCPs are exclusively located outside the participant's country of residence, where applicable","18 Years",{"count":63,"type":23},105,"OBSERVATIONAL","The goal of this observational pilot study is to evaluate whether a participant-mediated, direct-to-participant research approach is a feasible and effective way to collect health data from adults living with obesity in England, France, and Germany. This approach allows participants to take part remotely and to help researchers access their medical records using their data access rights, while also providing information directly through an online questionnaire.\n\nThe main questions it aims to answer are:\n\n1. Can medical records be successfully obtained through participant-authorized data subject access requests (DSARs), and how long does the process take? (In France, DSAR Authorization Form is not applicable and participants are asked to directly share their medical records of interest.)\n2. How well do healthcare providers comply with requests for medical records? (In France, DSAR Authorization Form is not applicable and participants are asked to directly share their medical records of interest. Therefore, their healthcare providers are not contacted.)\n3. Is the information collected through this approach complete and of sufficient quality for research purposes?\n4. How closely does information reported by participants match the information contained in their medical records?\n5. Are there differences in outcomes between countries and regions? Researchers will also explore the demographic, clinical and socio-economic characteristics of participants, assess health-related quality of life, evaluate experiences related to \"food noise\", and compare quality-of-life results across countries.\n\nThere is no comparison group or study treatment, as this is an observational study.\n\nParticipants will:\n\n* Provide electronic informed consent to participate in the study.\n* Authorize requests for their medical records using their legal right to access personal health information (DSAR). (In France, DSAR Authorization Form is not applicable and participants are asked to directly share their medical records of interest.)\n* Complete an online questionnaire about their health, quality of life, and experiences related to obesity.\n* Allow researchers to combine information from questionnaire with data obtained from their medical records.\n* Participate entirely remotely through the IQVIA Health Research Space (HRS) platform, with no study site visits required.\n\nParticipation lasts for up to 90 days and includes completion of questionnaire and the medical record retrieval process. The study plans to enroll approximately 105 participants, with around 35 participants in each participating country.",[30,67],"Overweight , Obesity",[69,70,71,72,73,74,75,76,77,78],"General Data Protection Regulation (GDPR)","Data Subject Access Request (DSAR) Authorization Form","patients-mediated Electronic Medical Records (EMRs)","Decentralized study","Direct to Participant (DtP)","Obesity","Observational study","Non-interventional study","Real-world study","Pilot study","NOT_YET_RECRUITING","2026-08-07",{"date":82,"type":44},"2026-08-12",{"date":84,"type":23},"2026-11",{"date":86,"type":23},"2027-03",{"name":88,"class":89},"IQVIA RDS Spain, SL","INDUSTRY",{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":96,"minAge":61,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":24,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":52},"100612738","phase-4-tirzepatides-role-in-postmenopausal-hr-breast-cancer-survivors-100612738","NCT07257484","Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors","Inclusion Criteria:\n\n* Biologically female\n* Age ≥ 18\n* Obesity as defined by current BMI ≥ 30 kg\u002Fm² or ≥ 27.5 kg\u002Fm² for individuals of Asian ancestry\n* Postmenopausal as defined by one or more of the following\n\n  * Age ≥60 years\n  * Age \\\u003C60 years with amenorrhea for ≥ 1 year\n  * Documented bilateral surgical oophorectomy\n  * Chemical menopause with the addition of LHRH agonists at least 12 weeks prior to enrolment, and plan to remain on LHRH agonists throughout the trial\n* HR+ (ER and\u002For PR) stage 0-III breast cancer\n* Completed curative treatment (surgery, chemotherapy, radiotherapy) at least 12 weeks prior to enrolment\n* Insurance approval for tirzepatide or willing to pay out of pocket\n* Willing to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Stage IV breast cancer\n* Concomitant use of CDK inhibitors\n* Concomitant use of antiHER2 therapy\n* The PI may be consulted regarding enrollment of females receiving other endocrine therapy medications\n* Other active malignancy requiring treatment\n* Enrollment in another investigational clinical trial\n* Contraindication to tirzepatide\n* Treatment with a GLP-1 receptor agonist within the last 3 months\n* Diabetes requiring insulin\n* Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol","FEMALE",{"count":98,"type":23},30,[100],"PHASE4","This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.",[30,103],"Breast Cancer",[105,106,107,108],"tirzepatide","hormone receptor positive","HR+","postmenopausal","2026-07-21",{"date":111,"type":44},"2026-07-22",{"date":113,"type":44},"2026-06-08",{"date":115,"type":23},"2028-02-25",{"name":117,"class":51},"Weill Medical College of Cornell University",{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":126,"targetDuration":128,"studyType":64,"phases":4,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":52},"100642092","precision-obesity-medicine-genetic-prediction-of-response-to-glp-1gip-agonists-100642092","NCT07653412","Precision Obesity Medicine: Genetic Prediction of Response to GLP-1\u002FGIP Agonists.","Prediction of Response to GLP-1\u002FGIP Receptor Agonists in Obesity Using Genetic Risk Score and SNP Profiling: A Prospective Cohort Study.","Diagenix","Inclusion Criteria:\n\n* Age ≥18 years\n* BMI ≥40 kg\u002Fm² or ≥37 kg\u002Fm² with comorbidities\n* Initiation of semaglutide or tirzepatide\n\nExclusion Criteria:\n\n* Prior bariatric surgery\n* Secondary causes of obesity\n* Active malignancy\n* Chronic pancreatitis\n* Family history of medullary thyroid carcinoma",{"count":127,"type":23},220,"6 Months","Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)\u002FGLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may contribute to these differences in treatment outcomes.\n\nThe aim of this prospective cohort study is to investigate whether a Genetic Risk Score (GRS) and selected obesity-related single nucleotide polymorphisms (SNPs) can predict weight loss response to semaglutide or tirzepatide in adults with obesity. Participants initiating treatment with either medication will undergo clinical, biochemical, and genetic assessment at baseline and will be followed for six months. The study will evaluate the association between genetic markers and treatment response and develop predictive models integrating genetic and clinical variables. The findings may contribute to the development of personalized treatment strategies for obesity.",[30,131,132],"Anti-obesity Agents","Precision Medicine",[74,134,132,36,135],"Genetic Risk Score","GIP\u002FGLP-1 Receptor Agonist","2026-07-08",{"date":138,"type":44},"2026-07-10",{"date":140,"type":44},"2026-04-22",{"date":142,"type":23},"2027-06-30",{"name":144,"class":51},"National and Kapodistrian University of Athens",{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":18,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":24,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":52},"100600321","continuous-glucose-monitoring-in-metabolic-surgery-100600321","NCT07095972","Continuous Glucose Monitoring in Metabolic Surgery","Optimizing Glycemic Control in Metabolic Surgery With Continuous Glucose Monitoring","Inclusion criteria: (1) age 20 to 60 years; (2) body mass index (BMI) ≥35 kg\u002Fm2\n\nExclusion Criteria:\n\n(1) age \\\u003C20 or \\>60 years; (2) confirmed type 1 diabetes; (3) pregnancy or breastfeeding; (4) history of hypersensitivity to any of the components of the subcutaneous infusions; (5) without access at home to a telephone or other factor likely to interfere with ability to participate reliably in the study; (6) history of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or potentially cause harm to the volunteer; (7) patients on insulin therapy before surgery; and (8) patients receiving revisional surgery.","20 Years","60 Years",{"count":155,"type":23},20,[26],"We will recruit 20 severely obese participants at Metamor Institute. Participants with obesity who are eligible for MBS will be randomized to either CGM group or self-monitoring of blood glucose (SMBG) group before the surgery based on a 1:1 ratio. All participants live in Baton Rouge, Louisiana. The surgeon in Metamor will introduce our study to the patients. If the patients are interested, the evaluation process includes verifying basic personal information, assessing health status and medical history, and evaluating specific eligibility criteria relevant to the study. The study coordinator will be discussing informed consent, ensuring participants understand the study's purpose, procedures, and any associated risks or benefits. Participants are encouraged to ask questions, ensuring clarity and comfort with the study. All collected data is documented and securely stored, respecting data privacy protocols. Eligible individuals are informed about the screening visit, while those not suitable are considered for future studies.",[30],[160,161,162,163,164],"Severe Obesity","Metabolic Surgery","Continuous Glucose Monitoring","Post-Bariatric Hypoglycemia","Randomized Controlled Trial","2026-07-07",{"date":167,"type":44},"2026-07-09",{"date":169,"type":23},"2026-08-15",{"date":171,"type":23},"2027-08-31",{"name":173,"class":51},"Pennington Biomedical Research Center",{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":24,"phases":183,"briefSummary":184,"conditions":185,"keywords":189,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":52},"100646879","dramatherapy-for-psychological-and-social-well-being-in-obesity-and-bariatric-care-100646879","NCT07685483","Dramatherapy for Psychological and Social Well-Being in Obesity and Bariatric Care","Effect of Dramatherapy Combined With Adapted Physical Activity on Psychological and Social Well-Being in Patients With Obesity and Eating Disorders in Medical and Bariatric Care: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 years or older.\n* Body mass index (BMI) ≥ 40 kg\u002Fm², or BMI ≥ 35 kg\u002Fm² with obesity-related comorbidities, or BMI ≥ 30 kg\u002Fm² with associated eating disorders or problematic eating behaviors.\n* Enrollment in a medical or bariatric care pathway at the Institut de l'Obésité, Clinique ELSAN Saint-Omer, including a therapeutic education program with adapted physical activity.\n* Availability and willingness to complete the planned study procedures and follow-up assessments.\n* Written informed consent provided after complete information about the study.\n* Affiliation to a social security system.\n\nExclusion Criteria:\n\n* Major medical contraindications to adapted physical activity or group sessions, including unstable cardiovascular disease or severe non-compensable locomotor limitations.\n* Severe psychiatric disorders or severe unstable eating disorders contraindicating bariatric surgery or preventing adequate participation in group sessions.\n* Major cognitive impairment or neuropsychological disorders preventing understanding of instructions or completion of assessments.\n* Unstable medical treatment or recent therapeutic modification likely to significantly affect body weight, fatigability, or mental health.\n* Inability to complete the full study protocol, including prolonged unavailability or planned relocation outside the region.\n* Refusal or inability to provide informed consent.\n* Major logistical barriers preventing access to the intervention site without feasible alternative arrangements.\n* Participation in a structured adapted physical activity program within the 3 months preceding inclusion.",{"count":182,"type":23},250,[26],"Obesity is currently a major public health challenge in France, particularly in the Hauts-de-France region, where prevalence exceeds 20% of the adult population. Bariatric surgery has considerably increased over the last two decades and is now recognized as an effective therapeutic option within a multidisciplinary care pathway. However, many patients continue to experience difficulties related to body image, emotional regulation, problematic eating behaviors, and long-term adherence to adapted physical activity (APA), which may limit the sustainability of treatment benefits. International literature highlights the importance of integrating psychological and psychosocial support alongside medical, nutritional, and physical interventions.\n\nThis monocentric randomized controlled trial aims to evaluate the effects of adding dramatherapy (DT) to a standardized APA program in adult patients with obesity enrolled in medical or bariatric care pathways at the Institut de l'Obésité of Clinique ELSAN Saint-Omer (France). Participants will be randomized to receive either standard APA alone or APA combined with DT. The intervention is designed to improve emotional expression, body perception, self-confidence, psychosocial well-being, and long-term adherence to care. Dramatherapy sessions will include theatrical expression, role play, improvisation, relaxation, and body-oriented creative exercises adapted to patients with obesity.\n\nThe primary objective is to evaluate the effect of DT on quality of life at the end of care, compared with APA alone, using the French version of the EQVOD questionnaire. Secondary objectives include the evaluation of eating behaviors and problematic eating regulation (TFEQ-R18, SCOFF), body image and body-related quality of life (BIQLI), self-efficacy (GSES), anxiety and depressive symptoms (BDI-II), adherence to APA programs, and anthropometric parameters such as body mass index, abdominal circumference, and body composition. Assessments will be conducted at baseline, at the end of the intervention, and at 6- and 12-month follow-up.\n\nThe study also includes a complementary qualitative component based on semi-structured interviews, ethnographic observation, body mapping, and identity boxes in order to explore patients' subjective experiences, psychosocial trajectories, and perceived impact of the intervention. Quantitative and qualitative data will be analyzed using a mixed-methods approach. A total of 250 participants are expected to be included. This study seeks to provide evidence regarding the potential added value of integrating dramatherapy into obesity and bariatric care pathways.",[30,186,187,188],"Obesity & Overweight","Eating Disorders","Bariatric Surgery",[74,187,188,190,191,192,193,194,195,196,197],"Dramatherapy","Art Therapy","Adapted Physical Activity","Body image","Quality of life","Psychosocial Well-Being","Psychosocial intervention","Body Mapping","2026-07-01",{"date":200,"type":44},"2026-07-06",{"date":202,"type":44},"2026-06-30",{"date":204,"type":23},"2029-05",{"name":206,"class":51},"Universite du Littoral Cote d'Opale",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":214,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":215,"targetDuration":217,"studyType":64,"phases":4,"briefSummary":218,"conditions":219,"keywords":223,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100644912","faisalabad-initiative-of-research-and-management-of-ncds-100644912","NCT07676214","Faisalabad Initiative of Research and Management of NCDs","FIRM-NCD","Inclusion Criteria:\n\nAge: 18 years and above Gender: Both male and female Permanent residents of the selected study areas Willing to participate and provide informed consent\n\nExclusion Criteria:\n\nPregnant and lactating women Oral and injectable contraceptive users Individuals with severe physical or cognitive impairments that prevent them from providing informed consent or participating in the screening procedures Individuals with implanted electronic medical devices (e.g., pacemakers or implantable cardioverter-defibrillators) will not undergo bioelectrical impedance analysis (BIA) for body composition assessment.",true,{"count":216,"type":23},3000,"3 Months","The burden of noncommunicable diseases (NCDs) continues to rise globally, and they have become the leading cause of morbidity and mortality, accounting for over 70% of deaths worldwide¹. Rapid lifestyle transitions and increasing urbanization have disproportionately affected low- and middle-income countries, which now bear a substantial share of the global NCD burden.\n\nPakistan, with a population of 241.5 million, is experiencing a double burden of both communicable diseases and NCDs¹³. The widespread adoption of sedentary lifestyles and unhealthy dietary patterns has contributed to a marked increase in NCDs across the country².\n\nAccording to the WHO Hypertension profile 2025, it is the most prevalent NCD in Pakistan, affecting approximately 42% (41% males and 44% females) of the population¹¹, followed by diabetes, with a reported prevalence of 30.8%¹². Additionally, a recent cross-sectional study among adults attending a tertiary care hospital in Islamabad reported dyslipidemia in 71.6% of men and 78.4% of women, indicating a substantial underlying community burden³. Pakistan also ranks tenth among 188 countries in terms of overweight and obesity prevalence, with nearly half of its population classified as overweight or obese⁴. According to World Health Organization data, 58.1% of Pakistanis are overweight, and 43.9% fall within the obese category⁴.\n\nDespite their profound public health and economic implications, efforts to address NCDs remain fragmented and insufficient.17 There remains a significant research gap in community-based NCD screening initiatives, particularly within the suburban and peri-urban communities of Faisalabad creating an unmet need to initiate a preventive strategy at community level to raise awareness about these diseases. This direction will minimize the increasing incidence and prevalence of NCDs and will ensure the quality health outcomes for better future.\n\nTimely identification of these diseases through screening is a critical step in reducing their impact on individuals and societies. Early detection enables cost-effective management, improved patient outcomes and a higher quality of life.14 One of the most important ways of reducing deaths from noncommunicable diseases (NCDs) is to control the risk factors that lead to their development.6 In this context, the present study aims to evaluate a community-based project focusing on disease awareness, screening, and structured referral to trained treating physicians for early diagnosis and management of major NCDs. The findings are expected to inform scalable, evidence-based interventions to reduce NCD burden and improve population health outcomes in Pakistan.",[220,221,222,30],"Diabete Mellitus","Hypertension","Hypercholerolemia",[224,225,221,74,226],"community screening","Diabetes","Hypercholestrolemia","2026-06-24",{"date":202,"type":44},{"date":230,"type":23},"2026-08-01",{"date":232,"type":23},"2027-12-31",{"name":234,"class":89},"Getz Pharma",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":214,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":24,"phases":243,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":52},"100610397","optimizing-self-monitoring-feedback-delivery-for-the-treatment-of-overweight-and-obesity-100610397","NCT07227051","Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity","Inclusion Criteria:\n\n* Age greater than or equal to 18 years\n* BMI greater than or equal to 25.0 kg\u002Fm2\n* Weight less than or equal to 175 kg (due to scale limit)\n* Own a smartphone compatible with Fitbit (e.g., an Apple iPhone running iOS 16.4 or higher or Android smartphone running Android 11 or higher) with a cellular and data plan\n\nExclusion Criteria:\n\n* Weight greater than 175 kg (due to a weight limit of the study-provided scale)\n* Smartphone device owned deemed incompatible with the Fitbit App\n* History of bariatric surgery or plans to obtain bariatric surgery during the study period\n* Current use of weight loss medications, or use of weight loss medications in the 6 months prior to initial pre-screening\n* Currently participating in a weight-loss program\n* Weight loss of greater than or equal to 10 lbs in the 6 months prior to initial pre-screening\n* Physical limitations that prevent walking at a brisk pace for at least 10 minutes without stopping\n* Use of a pacemaker or other implanted medical device\n* Currently pregnant\n* Currently breastfeeding\n* Less than 1-year post-partum\n* Plans to become pregnant within the study period\n* Lack of written confirmation that the potential participant has discussed study participation with their physician if they have been diagnosed with diabetes, hypertension, or has have a history of coronary heart disease\n* One or more study participants living in the household (enrollment limited to one participant per household)\n* Medical conditions that contraindicate weight loss or prevent completion of the study (e.g., current diagnosis of cancer or terminal illness, dementia, etc.)\n* Recent (in the past 6 months) changes in medications that affect weight\n* Self-reported eating disorder within past 5 years\n* Unable to complete the 17-week study (due to plans to relocate during the study period, etc.)\n* Unable or unwilling to provide informed consent\n* Unable to read English at the 5th grade level\n* Unwilling to accept random assignment\n* Unable or unwilling to download the study smartphone application, wear the physical activity monitor, or use the study e-scale\n* Failure to complete baseline assessment measures\n* Failure to complete at least 4 out of 6 days of self-monitoring dietary and weight self-monitoring during the behavioral run-in period\n* Any other condition(s) which, in the opinion of the Principal Investigator, would adversely affect participation in the study",{"count":242,"type":23},300,[26],"The purpose of this research study is to learn how to best provide weekly feedback on individual progress toward intervention goals during a weight loss program.",[186,30],[247,248,249,250,251,252,253,254,255,256,257],"weight loss","self-monitoring","smartphone app","lifestyle intervention","digital health","mHealth","physical activity","dietary change","e-scale","wearables","activity monitor","2026-06-23",{"date":227,"type":44},{"date":261,"type":44},"2026-01-26",{"date":263,"type":23},"2028-02-28",{"name":265,"class":51},"Wake Forest University Health Sciences",{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":24,"phases":276,"briefSummary":277,"conditions":278,"keywords":281,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":52},"100643847","3d-reconstruction-vr-and-machine-learning-in-body-image-in-bariatrics-100643847","NCT07668492","3D Reconstruction, VR and Machine Learning in Body Image in Bariatrics","The Use of 3D Reconstruction, Virtual Reality, and Machine Learning in Addressing Body Image in Bariatric Metabolic Surgery.","Inclusion Criteria:\n\n* Tier 4 bariatric group\n* On waiting list for bariatric metabolic surgery\n* Able to stand unaided for at least 5 minutes\n\nExclusion Criteria:\n\n* Anyone who cannot provide informed consent\n* Anyone who is involved in current research or has recently been involved in any research prior to recruitment.","75 Years",{"count":275,"type":23},80,[26],"Studies have shown that following bariatric metabolic surgery (BMS), patients continue to experience dissatisfaction with their new body image and identity). The reason for this is poorly understood but negative body image perception after surgery is linked to poor psychological and clinical outcomes. Our pilot study looking at the acceptability and feasibility of 3D reconstruction and virtual reality (VR) in addressing body image in BMS found that participants felt better informed about how their body will change following significant weight loss and agreed this novel intervention would be beneficial in helping patients adjust to changes in their body after BMS.\n\nThe investigators propose a randomised control trial comparing group body image counselling and group body image counselling with 3D reconstruction and VR in addressing body image in BMS. The study aims to enrol 80 participants from the Tier 4 bariatric group at St Mary's Hospital and Chelsea \\& Westminster Hospital. After consent, participants will be divided into two groups: the control group will receive traditional group body image counselling, and the intervention group will receive the same counselling supplemented with VR and 3D reconstructed images depicting 15% and 25% total less body weight. Both groups will undergo four sessions over six months.\n\nThe investigators will collect data including body measurements and 3D images of the participant in their underwear using a secure password protected device at baseline and follow participants at 3, 6, 9, 12, 18, 24, and 36 months post-BMS. Patient reported outcomes will be assessed through patient-reported questionnaires.\n\nThis trial seeks to determine if integrating 3D reconstruction and VR technology into body image counselling can provide better support for patients adjusting to body image changes post-BMS, potentially leading to improved psychological and clinical outcomes.",[30,279,280,188],"Body Image","Mental Health",[282,283,279,284,285],"3D Reconstruction","Virtual Reality","Machine Learning","Bariatric Metabolic Surgery","2026-06-19",{"date":288,"type":44},"2026-06-25",{"date":290,"type":23},"2026-06",{"date":292,"type":23},"2030-03",{"name":294,"class":51},"Imperial College London",{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":96,"minAge":61,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":24,"phases":304,"briefSummary":305,"conditions":306,"keywords":307,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":52},"100644335","targeting-sedentary-behavior-reduction-and-physical-fitness-enhancement-in-women-before-and-beyond-bariatric-surgery--barimov-study-protocol-100644335","NCT07663942","Targeting Sedentary Behavior Reduction and Physical Fitness Enhancement in Women Before and Beyond Bariatric Surgery- BARIMOV Study Protocol","BARIMOV","Inclusion Criteria:\n\n* Adult women (≥ 18 years);\n* BMI of 30-45 kg\u002Fm2;\n* Scheduled for primary vertical sleeve gastrectomy or Roux-en-Y gastric bypass;\n* Capacity to provide informed consent, adequate proficiency in the national language;\n* Access to the internet and mobile phone communication.\n\nExclusion Criteria:\n\n* Previous bariatric surgery or gastric surgical procedure;\n* Physical incapacity or medical contraindications precluding physical fitness testing or participation (active cardiac disease, uncontrolled hypertension, severe joint disease);\n* Pregnancy or breastfeeding;\n* Inability to provide informed consent or comply with study procedures;\n* Patients with type 1 or 2 diabetes mellitus.",{"count":303,"type":23},72,[26],"Introduction: Sedentary behavior (SB) and insufficient physical activity (PA) interact to worsen physical fitness (PF), obesity-related complications and diseases (ORCD), and all-cause mortality in women with obesity. Replacing SB with low-intensity PA may improve PF and ameliorate ORCD, with potential lasting effects after bariatric surgery (BS). However, strong evidence on how PF influences BS outcomes and whether preoperative PA interventions can improve postoperative outcomes is lacking. The BARIMOV study aims to evaluate the effects of a structured sedentary behavior reduction program (SBRPro) on PF, investigate whether PF improvements influence BS outcomes, and explore potential mechanistic pathways by characterizing molecular adaptations in peripheral blood, skeletal muscle, and visceral adipose tissue (VAT).\n\nMethods: BARIMOV is a prospective cohort study with five assessment time points. Adult women (≥18 years) with BMI 30-45 kg\u002Fm² scheduled for BS will be recruited (n = 72). At T0, participants will undergo a baseline assessment of PF - body composition, muscle strength, cardiorespiratory fitness - PA patterns, and ORCD screening. Participants will be instructed in the SBRPro and asked to maintain weekly PA diaries throughout the pre- and post-operative periods. At T1, adherence to SBRPro will be evaluated via diary review and PF reassessment, to enable participants' allocation into two adherence-based groups. At T2, during surgery, skeletal muscle and VAT biopsies will be collected for proteomic analysis to compare molecular adaptations of adherent and non-adherent groups. At T3 and T4, primary outcomes, including weight loss, body composition, ORCD, and quality of life (QoL), will be evaluated at 3±1 and 12±1 months postoperatively, respectively. Blood multiomics profiling will be performed at T0, T1, and T3 to explore dynamic changes in systemic metabolic pathways over time.\n\nConclusion: This study will determine whether PF improvement, achieved through structured SB reduction and PA engagement, is associated with better BS outcomes. By integrating clinical and molecular endpoints, the study will provide mechanistic insights into the pathways by which PF enhances BS outcomes and inform physical activity intervention strategies.",[30],[308,247,309,310,311,312],"physical inactivity","quality of life","adiposity","skeletal muscle","adipose tissue","2026-06-17",{"date":258,"type":44},{"date":316,"type":44},"2026-04-20",{"date":318,"type":23},"2031-04-20",{"name":320,"class":51},"Hospital de Sao Sebastiao",{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":273,"enrollmentInfo":327,"targetDuration":329,"studyType":64,"phases":4,"briefSummary":330,"conditions":331,"keywords":332,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":52},"100627396","real-world-case-registry-study-on-obesity-100627396","NCT07448090","Real-World Case Registry Study on Obesity","Inclusion Criteria:\n\n1. Age 18 years and above, gender not restricted;\n2. Weight fluctuation within the last 3 months is ≤ 5% and BMI is ≥ 28.0 kg\u002Fm2;\n3. Good compliance, willing to follow the follow-up principles;\n4. Agree to sign the informed consent form.\n\nExclusion Criteria:\n\n1. Co-existing severe diseases of the heart, liver, lungs, kidneys, brain, blood, neuro-psychiatric system, or other vital organs.\n2. Secondary obesity (obesity attributable to another clearly diagnosed disorder, e.g., hypothalamic or pituitary inflammation, tumours or trauma, Cushing's syndrome, hypothyroidism, hypogonadism, polycystic ovary syndrome, etc.).\n3. Iatrogenic obesity (obesity resulting from drugs or therapeutic interventions administered for other conditions).\n4. Pregnant or lactating women.\n5. Subjects whom the investigator deems unsuitable for participation in this study.",{"count":328,"type":23},10000,"24 Weeks","Obesity is a major risk factor for cardiovascular disease, diabetes, cancer, and other chronic conditions. Due to its complex etiology and frequent comorbidities, effective obesity management requires comprehensive and individualized approaches. This study is a multicenter, prospective, real-world registry designed to evaluate integrated traditional Chinese medicine (TCM) and Western medicine interventions for obesity.\n\nThe study will enroll at least 10,000 individuals with obesity from urban and rural populations. Multimodal data, including electronic medical records, laboratory test results, imaging data, and lifestyle information, will be collected. The effectiveness of integrated TCM and Western medicine interventions will be assessed across different age groups, disease stages, and obesity-related constitution types. In addition, disease progression patterns and key prevention and treatment points will be explored. Health economic analyses will be conducted to evaluate the cost-effectiveness of different obesity management strategies, providing real-world evidence to support public health policy and the optimization of integrated obesity prevention and management approaches.",[186,30],[74,333,334,335,336],"Real-World Study","Integrated Traditional Chinese and Western Medicine","Prospective Cohort","Registry Study","2026-06-10",{"date":339,"type":44},"2026-06-12",{"date":341,"type":44},"2024-08-31",{"date":343,"type":23},"2028-07-31",{"name":345,"class":51},"Hubei Hospital of Traditional Chinese Medicine",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":18,"minAge":152,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":24,"phases":356,"briefSummary":350,"conditions":357,"keywords":359,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":52},"100638714","improving-outcomes-after-af-ablation-in-obese-patients-100638714","NCT07618741","Improving Outcomes After AF Ablation in Obese Patients","Outcome Improvement in Obese Patients With Atrial Fibrillation After Catheter Ablation: Importance of Gut Microbiota Dysbiosis and Adipose Tissue Biology","OBESE-AF","Inclusion Criteria:\n\n* Patients with Class I indication of catheter ablation of paroxysmal or persistent AF and will undergo catheter ablation at National Taiwan University Hospital.\n\nExclusion Criteria:\n\n1. Informed consent could not be obtained due to personal problem\n2. Unwillingness or inability to return for follow-up visits or reason to believe that adherence to follow-up visits wound be irregular\n3. Current or scheduled enrollment in other conflicting studies, and\n4. Concomitant disease or other medical condition likely to result in death within 6 months",{"count":355,"type":23},520,[26],[358,30],"Atrial Fibrillation (AF)",[360,361,74,362,363,364,365,366],"Atrial fibrillation","Catheter ablation","Gut microbiota dysbiosis","Epicardial adipose tissue","Cardiac rehabilitation","Lifestyle modification","Left atrial remodeling","2026-05-24",{"date":369,"type":44},"2026-06-01",{"date":371,"type":44},"2021-09-16",{"date":373,"type":23},"2030-05",{"name":375,"class":51},"National Taiwan University Hospital",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":24,"phases":385,"briefSummary":386,"conditions":387,"keywords":389,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":52},"100617322","side-to-side-duodeno-ileostomy-versus-semaglutide-in-adults-with-obesity-and-type-2-diabetes-100617322","NCT07317115","Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes","Magnetic Compression Anastomosis in Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes (MAGvMED Study)","MAGvMED","Inclusion Criteria:\n\n* Body Mass Index (BMI) between 30 - 40 kg\u002Fm2 and qualifies for obesity treatment at the discretion of the treating investigator (i.e., must be assessed to qualify for both surgery and medication treatment to justify randomization).\n* Type 2 diabetes (T2D defined as HbA1c ≥ 6.5%).\n* Participant agrees to refrain from additional metabolic and bariatric (MBS) or reconstructive surgery that would affect body weight for the duration of the study.\n* Participant agrees to refrain from taking any additional semaglutide-containing or other GLP-1RA medication for the duration of the study, regardless of randomization assignment (i.e., Surgery or Medication).\n\nParticipant has been informed of the nature of the study and is willing and able to comply with requirements, including randomization, and provides written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Meets any of the contraindications for either treatment arm (Surgery: Magnet System; or Medication: semaglutide), thereby prohibiting randomization\n* Current or previous metabolic and bariatric surgery (MBS) treatment in the previous 12 months (e.g., sleeve gastrectomy, intragastric balloons, adjustable gastric banding).\n* Taking or treated with semaglutide, semaglutide-containing medications, or any other GLP-1RA medication in the previous 12 months.\n* Pregnant, lactating or planning pregnancy during the clinical study and follow-up period.\n* Currently participating in an investigational drug, biologic, or medical device or other interventional clinical study.\n* Presence of other anatomic or comorbid conditions, or medical, social or psychological conditions that, in the investigator's opinion, would contraindicate either treatment arm or could limit the participant's ability to participate in the clinical study or to comply with follow-up requirements.",{"count":155,"type":23},[26],"Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).",[30,186,388],"Type 2 Diabetes (T2DM)",[390,37,391],"Magnet System","GT Metabolic Solutions, Inc.","2026-05-18",{"date":394,"type":44},"2026-05-19",{"date":396,"type":44},"2026-03-18",{"date":398,"type":23},"2028-06",{"name":391,"class":89},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":408,"targetDuration":409,"studyType":64,"phases":4,"briefSummary":410,"conditions":411,"keywords":423,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":451,"locationsCount":52},"100636568","cartiz-registry-cartilage-arthropathy-and-imaging-under-tirzepatide-in-zone-stratified-cohorts---a-four-institute-mexican-observational-registry-100636568","NCT07567378","CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry","Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts (CARTIZ): A Prospective Observational Multi-Institutional Registry of the VAT-Articular-Cardiac-Aging Axis in Adults Exposed to Tirzepatide in Mexico, With Quantitative Knee Cartilage T2 Mapping, Cardiac CT Epicardial Adipose Tissue Radiomic Phenotyping, HLA Stratification, Longitudinal Multi-Frequency Bioimpedance Body Composition, and a Prespecified Surgical Tissue Acquisition Subcohort","CARTIZ","Inclusion Criteria:\n\n* 1\\. Age ≥18 years at the time of informed consent. 2. Currently receiving tirzepatide under an independent clinical indication (type 2 diabetes, insulin resistance, obesity with or without associated metabolic disease, renal protection, metabolic hypertension, or associated off-label metabolic use) prescribed by the treating physician independently of the registry.\n\n  3\\. Presence of at least one objectively documented musculoskeletal manifestation - current or historical - defined as any of: (i) inflammatory arthralgia affecting one or more joints with clinical, imaging, or serological support; (ii) CASPAR-positive psoriatic arthritis; (iii) radiographically documented knee osteoarthritis; (iv) enthesitis on physical examination or ultrasound; (v) documented inflammatory arthropathy of the spine or peripheral joints with a specialist diagnosis.\n\n  4\\. For the retrospective-prospective component: availability of clinical documentation of articular state prior to tirzepatide initiation in the patient's medical record. Documentation may include physical examination notes, imaging, laboratory values, or specialist consultation notes.\n\n  5\\. Signed informed consent for registry enrolment, longitudinal serum biobanking, HLA typing at INCMNSZ, quantitative knee MRI with T2 mapping at Ci3M UAM-Iztapalapa at Week 0 and Week 52, non-contrast cardiac CT at INCar at Week 0 and Week 52, multi-frequency bioelectrical impedance analysis at Universidad La Salle México at six timepoints, and (where applicable) medical record review. Each attestation is consented modularly within a single document.\n\n  6\\. Clinical plan to continue tirzepatide for at least 52 weeks from registry Week 0, based on the treating physician's evaluation of current clinical indication. Discontinuation during follow-up is captured as an outcome variable and does not remove the patient from the registry.\n\n  7\\. Capacity to attend scheduled follow-up visits and to undergo bilateral knee MRI at Ci3M (without severe claustrophobia requiring sedation, without absolute contraindication to MRI - see Exclusion 6) and non-contrast cardiac CT at INCar (without uncontrolled arrhythmia precluding ECG-gated imaging of diagnostic quality).\n\nFor the Surgical Tissue Subcohort (Cohort 3) only - additional criteria applied at the time of subcohort enrolment:\n\n8s. Scheduled clinically indicated cardiac surgery at the Instituto Nacional de Cardiología Ignacio Chávez (coronary artery bypass grafting, valve replacement, or combined procedures) during registry follow-up.\n\n9s. Specific additional informed consent for intraoperative collection of epicardial adipose tissue fragments.\n\nExclusion Criteria:\n\n* 1\\. Initiation or modification of a biologic disease-modifying antirheumatic drug (biologic DMARD) or JAK inhibitor within the 12 weeks prior to Week 0, or clinically anticipated initiation or modification during the first 12 weeks of follow-up. Washout may permit re-screening.\n\n  2\\. Major joint surgery within the 3 months prior to Week 0, or planned major joint surgery within the 12 months following Week 0, involving any joint scheduled for evaluation in the registry.\n\n  3\\. Intra-articular corticosteroid or hyaluronic acid injection within the 6 weeks prior to baseline biospecimen collection in any joint. Patients beyond the 6-week washout are eligible.\n\n  4\\. Active malignancy, with the exception of adequately treated non-melanoma skin carcinoma. History of malignancy in remission ≥5 years is permitted at the discretion of the treating investigator.\n\n  5\\. Current pregnancy, lactation, or planned pregnancy within the 12-month observation period.\n\n  6\\. Absolute contraindication to MRI, including non-MRI-compatible cardiac pacemaker or implanted defibrillator, ferromagnetic intracranial vascular clips, non-documented non-MRI-compatible cochlear implants, or other contraindication per the local MRI safety protocol.\n\n  7\\. Systemic rheumatologic disease other than psoriatic arthritis or osteoarthritis requiring active immunomodulation, specifically: seropositive rheumatoid arthritis on biologic therapy, active systemic lupus erythematosus on immunomodulation, active vasculitis on immunosuppression, or other systemic disease whose treatment confounds the inflammatory axis the registry is designed to characterize.\n\n  8\\. Inability to provide informed consent (cognitive impairment, language barrier not resolvable with site interpreter, or other incapacity to understand the protocol), or anticipated inability to complete the 52-week follow-up.\n\nFor the Surgical Tissue Subcohort (Cohort 3) only - additional exclusions:\n\n9s. Prior major cardiac surgery resulting in extensive pericardial adhesions that preclude safe intraoperative EAT fragment collection, as assessed by the operating cardiac surgeon.\n\n10s. Emergency cardiac surgery precluding the specific informed consent process.",{"count":98,"type":23},"52 Weeks","CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1\u002FGIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance, obesity, renal protection, metabolic hypertension, or associated off-label metabolic use. The registry is entirely observational: CARTIZ does not initiate, modify, interrupt, or supply tirzepatide, and does not dictate dose, route, or duration. All pharmacological exposure decisions are made by the treating physician independently of study participation. The registry is operationalized through a four-institute architecture integrating three Mexican National Institutes of Health and one national imaging laboratory. Core 1 (Knee Cartilage Imaging, Ci3M UAM-Iztapalapa) performs bilateral 3T MRI with quantitative T2 mapping at Week 0 and Week 52. Core 2 (Cardiac Imaging, Instituto Nacional de Cardiología Ignacio Chávez) performs non-contrast cardiac computed tomography for radiomic phenotyping of epicardial adipose tissue at Week 0 and Week 52 under cardiovascular Co-Principal Investigator Dr. Erick Alexánderson Rosas. Core 3 (HLA Typing, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Transplant Department) performs Class I and Class II HLA typing by PCR-SSO Reverse Luminex. Core 4 (Body Composition, Universidad La Salle México) performs multi-frequency bioelectrical impedance analysis (seca mBCA) at six longitudinal timepoints capturing visceral adipose tissue trajectory, phase-angle trajectory, appendicular skeletal muscle mass, and hydration ratios at zero marginal cost. The registry enrolls n=30 patients across three clinical sites with identical protocol (IMSS Clínica Río Magdalena, INCMNSZ outpatient clinic, and a private practice site in Mexico City), generating 60 evaluable knees and 30 paired cardiac CT studies. The primary co-endpoints address a mechanistic question no other tirzepatide study is positioned to answer: whether the articular response to tirzepatide in inflammatory arthropathy precedes and mechanistically precedes weight loss, through formal mediation analysis of Week-4 ACR20 response via high-sensitivity C-reactive protein, SERPINB2, and dipeptidyl peptidase-4 activity, restricted to the Mechanistic Analysis Set of patients with tirzepatide exposure ≤16 weeks at Week 0 and delta-BMI \\\u003C1.0 kg\u002Fm² through Week 4. A prespecified Surgical Tissue Subcohort is declared at initial registration to establish public scientific priority on direct human epicardial adipose tissue transcriptomic characterization under dual GIP\u002FGLP-1 receptor agonism. Subcohort participants who undergo clinically indicated cardiac surgery at INCar during follow-up (coronary artery bypass grafting, valve replacement, or combined procedures) are invited to provide specific additional informed consent for collection of epicardial adipose tissue fragments routinely excised during operative access and otherwise discarded as surgical waste. Operational launch is contingent on separate INCar tissue-specific approvals and will proceed via PRS record amendment when ready",[412,413,414,415,29,30,416,32,417,418,419,358,420,421,422],"Psoriatic Arthritis","Osteoarthitis","Knee","Diabetes (DM)","Insulin Resistance Syndrome","Heart Failure","Preserved Ejection Fraction","Coronary Artery Disease","Non Alcholic Fatty Liver Disease","Sarcopenia","Pericardium",[424,425,426,427,428,429,430,431,363,432,433,434,435,436,437,438,439,440,441,442,443,444],"Tirzepatide","Dual GIP\u002FGLP-1 receptor agonist","Multi-nutrient-stimulated hormones","Psoriatic arthritis","Inflammatory arthropathy","ACR20","Cartilage T2 mapping","Quantitative knee MRI","Cardiac CT radiomics","Fat Attenuation Index","HLA typing","Visceral adipose tissue","Phase angle","seca mBCA","Bioelectrical impedance analysis","Mediation analysis","Weight-independent effect","Off-label exposure","Mexican registry","Epicardial adipose transcriptomics","Single-nucleus RNA sequencing","2026-05-07",{"date":447,"type":44},"2026-05-12",{"date":449,"type":23},"2026-05",{"date":204,"type":23},{"name":452,"class":51},"JULIO GRANADOS MONTIEL",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":24,"phases":463,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":479,"leadSponsor":481,"locationsCount":52},"100640068","hormonal-and-microbiota-modulation-after-endoscopic-sleeve-gastroplasty-100640068","NCT07576777","Hormonal and Microbiota Modulation After Endoscopic Sleeve Gastroplasty","Roles of Hormonal Modulation and the Microbiota in Gastric Emptying and Metabolic Response After Endoscopic Sleeve Gastroplasty","HOVIGAMI-ESG","Inclusion Criteria:\n\n* Male or female, age ≥ 18 years\n* BMI between 30 and 40 kg\u002Fm²\n* With or without obesity-related comorbidities (hypertension, diabetes, -obstructive sleep apnea, etc.)\n* Indication for ESG (Endoscopic Sleeve Gastroplasty) or surgical sleeve gastrectomy validated in a multidisciplinary team meeting\n* Patient with an indication to undergo CT scan and scintigraphy\n* Written informed consent\n* Affiliation with a health insurance system\n\nExclusion Criteria:\n\n* Patient receiving anti-obesity treatment (GLP-1 analogs, multi-agonists)\n* History of prior gastric surgery\n* History of gastric or distal esophageal cancer\n* History of gastric dysplasia\n* Presence of a hiatal hernia \\> 2 cm\n* Contraindication to general anesthesia, including:\n\n  * Severe coagulation disorders, including uncontrolled congenital or acquired hemostasis disorders, severe thrombocytopenia (platelets \\\u003C 50 G\u002FL), non-interruptible anticoagulant or antiplatelet therapy according to current guidelines, uncorrected INR \\> 1.5\n  * Hemodynamic instability, defined as persistent hypotension or shock, uncontrolled cardiac arrhythmias, or need for vasopressor support\n  * Decompensated cardiac disease, including uncontrolled heart failure (NYHA III-IV), unstable ischemic heart disease or recent acute coronary syndrome, untreated severe valvular disease, uncontrolled severe hypertension\n  * Decompensated respiratory disease, including acute or severe chronic respiratory failure not stabilized, uncontrolled severe COPD, untreated severe obstructive sleep apnea, persistent hypoxemia requiring high-flow oxygen therapy\n  * Any other clinical condition considered incompatible with general anesthesia or endoscopy by the anesthesiologist or investigator, according to current guidelines and patient safety considerations Significant or unstable renal insufficiency, or history of severe reaction to iodinated contrast agents\n* Participation in another clinical research study, except for non-interventional studies\n* Patient under legal protection (guardianship, curatorship, or judicial protection)\n* Physical inability to provide written informed consent\n* Rare forms of obesity of genetic and\u002For central origin (e.g., associated with craniopharyngioma)\n* Pregnancy or breastfeeding\n* State medical aid (AME)",{"count":462,"type":23},40,[26],"Obesity is a chronic disease with a rapidly increasing prevalence, expected to affect up to 25% of the French population by 2030, and is associated with significant morbidity, mortality, and healthcare burden. Bariatric surgery, including sleeve gastrectomy and gastric bypass, remains the standard treatment for severe obesity but is irreversible and carries procedural risks.\n\nLess invasive alternatives have emerged, including pharmacological treatments (GLP-1 receptor agonists and multi-agonists) and endoscopic approaches such as endoscopic sleeve gastroplasty (ESG), which have shown efficacy in weight loss and metabolic improvement, although drug therapies are limited by weight regain after discontinuation.\n\nSleeve gastrectomy, the most frequently performed bariatric procedure in France, induces weight loss through gastric restriction and hormonal changes, including decreased ghrelin and increased GLP-1 and PYY, along with accelerated gastric emptying.\n\nESG is a minimally invasive endoscopic technique with mechanisms that remain incompletely understood, likely involving gastric restriction, altered gastric emptying, and hormonal and microbiome-related effects.\n\nBariatric outcomes are driven by complex interactions between gastric anatomy, motility, hormonal regulation, and the gut microbiome. An integrated evaluation of these parameters is needed to better understand response variability after intervention.\n\nA total of 40 patients will be enrolled (20 per group).",[30,466],"Metabolic Disorders",[74,468,469,470,471,472,473,474],"Endoscopic Sleeve Gastroplasty","Sleeve Gastrectomy","Gastric Emptying","Gut Hormones","Gastric Microbiota","Weight Loss","Metabolic Response","2026-05-04",{"date":477,"type":44},"2026-05-08",{"date":475,"type":23},{"date":480,"type":23},"2029-05-04",{"name":482,"class":51},"Assistance Publique - Hôpitaux de Paris",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":24,"phases":492,"briefSummary":493,"conditions":494,"keywords":495,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":52},"100603060","effects-of-bariatric-surgery-on-cardiovascular-risk-profile-in-relation-to-inflammatory-parameters-endothelial-phenotyping-and-analysis-of-the-cross-talk-between-adipose-tissue-and-endothelium-100603060","NCT07131605","Effects of Bariatric Surgery on Cardiovascular Risk Profile in Relation to Inflammatory Parameters: Endothelial Phenotyping and Analysis of the Cross-talk Between Adipose Tissue and Endothelium","BARIHEART","Inclusion Criteria:\n\nAdults (≥ 18 years old); Patients with obesity (Body Mass Index ≥ 30 kg\u002Fm²); Patients scheduled to undergo bariatric surgery via mini-gastric bypass or sleeve gastrectomy; Patients able to give their consent and to provide signed and dated informed consent for the processing of personal data; Willingness to attend follow-up visits and undergo all assessments required by the study protocol.\n\nExclusion Criteria:\n\nActive systemic inflammatory diseases (e.g., chronic inflammatory bowel diseases, chronic rheumatologic diseases); Acute or chronic infections Severe anemia or coagulation disorders; Moderate to severe chronic kidney disease; Active malignancies.",{"count":491,"type":23},85,[26],"This research project aims to study how obesity affects the heart and metabolism, and how these effects change after significant weight loss following bariatric surgery. In particular, we want to look at how blood vessels and fat tissue function in people with obesity, to detect early signs of vascular problems and understand how fat tissue communicates with blood vessels.\n\nOur main idea is that obesity disrupts the normal function of blood vessels, partly due to substances released by fat tissue and changes in gut bacteria. We believe that 6 and 12 months after surgery - with proper weight loss - these problems will gradually improve. We expect to see better blood vessel function and lower levels of inflammation and fat-related substances in the blood, which could significantly reduce the overall risk of heart disease.",[30],[496,497],"obesity","cardiovascular risk",{"date":477,"type":44},{"date":500,"type":44},"2024-11-11",{"date":502,"type":23},"2026-11-11",{"name":504,"class":51},"Maria Cecilia Hospital",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":513,"enrollmentInfo":514,"targetDuration":4,"studyType":24,"phases":516,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":52},"100634744","the-isar-inflex-trial-inflammation-and-exercise-100634744","NCT07543666","The ISAR InflEx Trial (Inflammation and Exercise)","Impact of Different Exercise Intensities and Durations on Systemic Inflammation - The ISAR InflEx Trial (Inflammation and Exercise) -","InflEx","Inclusion Criteria:\n\n* BMI 25.0 - 30.0 kg\u002Fm²\n* age 18 - 45 years\n* informed consent\n* no regular physical activity (≤1x\u002Fweek of structured exercise)\n* willingness to strictly follow and adhere to the intervention protocol for the entire study\n\nExclusion Criteria:\n\n* any acute or chronic illness\n* pregnancy and breastfeeding\n* active smoking\n* Regular use of medication","45 Years",{"count":515,"type":23},33,[26],"A sedentary lifestyle and obesity are associated with chronic low-grade inflammation and an elevated risk of cardiovascular disease (CVD). This study aims to systematically characterize and compare the effects of three distinct exercise modalities - moderate-intensity, vigorous-intensity, and short-duration maximal exercise - each differing in duration and intensity, on systemic inflammation and immune function. The study investigates the potential of exercise as an effective anti-inflammatory intervention for the prevention of CVD.",[519,30],"Inflammation",[521,522,496,253],"exercise","inflammation","2026-04-21",{"date":525,"type":44},"2026-04-24",{"date":527,"type":44},"2026-01-01",{"date":529,"type":23},"2027-06",{"name":531,"class":51},"Department of Cardiology German Heart Center Munich TUM University Hospital",{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":214,"sex":18,"minAge":539,"maxAge":540,"enrollmentInfo":541,"targetDuration":4,"studyType":24,"phases":542,"briefSummary":543,"conditions":544,"keywords":545,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":551,"leadSponsor":553,"locationsCount":555},"100634860","role-of-the-environment-in-pediatric-obesity-100634860","NCT07545174","Role of the Environment in Pediatric Obesity","REOP","Inclusion Criteria:\n\nPatient with Obesity disorder :\n\n* Children with obesity (according to the BMI curves of the International Obesity Task Force\u002FIOTF)\n* Follow-up within the obesity network of the Centre Val de Loire region (ObeCentre)\n\nControl group:\n\n* Children who are not obese (according to the BMI curves of the International Obesity Task Force\u002FIOTF)\n\nAll:\n\n* Children aged 6 to 15 at the time of inclusion (inclusive)\n* Whose two parents, or legal guardian, have signed an informed consent form\n* Patients affiliated with or covered by a social security system\n\nExclusion Criteria:\n\n* Disorder preventing understanding of trial information or informed consent.","6 Years","15 Years",{"count":275,"type":23},[26],"Childhood obesity is a particular concern in developed countries such as the United States, the United Kingdom, Canada, and certain European countries. According to the World Health Organization (WHO), approximately 6% of children under the age of 5 worldwide were obese in 2016, a figure that continues to rise.\n\nThe pathophysiology of pediatric obesity can be explained by several interconnected biological and behavioral mechanisms. In particular, it involves dysfunctions in the hormones that regulate appetite and satiety, as well as dysfunctions in lipid metabolism.\n\nPer- and polyfluoroalkyl substances (PFAS) are a large family of synthetic chemical compounds. The main PFAS are perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS), perfluorononanoic acid (PFNA), and perfluorohexanesulfonic acid (PFHxS). PFAS are present in many everyday consumer products.\n\nBisphenol A (BPA) is a chemical compound used primarily in the manufacture of plastics and resins. It is commonly found in polycarbonate plastics, used to make food containers and water bottles, as well as in epoxy resins, which are used to coat the inside of food cans and water pipes.\n\nNon-persistent pesticides, such as organophosphates and polychlorinated biphenyls, are chemicals used primarily in agriculture to control insects and other pests.\n\nThere are arguments suggesting that PFAS, bisphenol A, and non-persistent pesticides may play a role in the onset of pediatric obesity, particularly by acting.",[30],[74,546,547],"PFAS","Environment","2026-04-15",{"date":140,"type":44},{"date":290,"type":23},{"date":552,"type":23},"2029-06",{"name":554,"class":51},"University Hospital, Tours",2,{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":18,"minAge":564,"maxAge":20,"enrollmentInfo":565,"targetDuration":4,"studyType":24,"phases":566,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":582,"locationsCount":52},"100634683","iron-absorption-in-the-low-oxygen-exposure-and-weight-status-lows-study-100634683","NCT07542873","Iron Absorption in The Low Oxygen Exposure and Weight Status (LOWS) Study","Effects of Energy Restriction and Intermittent Hypoxia on Iron Absorption in Obesity","LOWS-IRON","Inclusion Criteria:\n\n* Obese (BMI between 30-39.9 kg\u002Fm2)\n* Born at altitudes below 2,100 meters (\\~7,000 feet)\n* Currently residing in Baton Rouge, Louisiana or surrounding area\n* Not taking any medication(s) that interfere with oxygen delivery\u002Ftransport for 4 weeks prior to and throughout the entire study (e.g., includes sedatives, sleeping aids, tranquilizers and\u002For any medication that depresses ventilation, diuretics, alpha and beta blockers).\n* Willing to refrain from smoking, vaping, chewing tobacco, and dietary supplement use throughout the entire study.\n* Willing to have a hypoxic tent set-up in their home and spend 8 consecutive hours per night in the tent for 8 weeks\n\nExclusion Criteria:\n\n* Living in areas that are more than 1,200 m (\\~4,000 feet), or have traveled to areas that are more than 1,200 m for five days or more within the last 2 months\n* Cardiovascular abnormalities, gastrointestinal disorders, or any condition that interferes with oxygen delivery\u002Ftransport (e.g., kidney disease, cardiovascular disease, etc.)\n* Oxygen saturation \\\u003C 95% while awake or oxygen saturation dips below 88% for a total of ≥ 10 min overnight in normoxic conditions\n* Evidence of apnea or other sleeping disorders\n* Evidence of prior high-altitude pulmonary edema (HAPE) or high-altitude cerebral edema (HACE) diagnosis\n* Diagnosis or family history of sickle cell anemia\u002Ftrait\n* Hematocrit \\\u003C42% for males, \\\u003C36% for females\n* Hemoglobin \\\u003C13 g\u002FdL for males, \\\u003C12 g\u002FdL for females\n* Blood donation within 8 weeks of beginning the study\n* Present condition of alcoholism, anabolic steroids, or other substance abuse issues\n* Women who are pregnant, lactating, planning to become pregnant, or who have had an irregular menstrual cycle in the past 6 mo.\n* Weight gain or loss \\> 10% of body weight during the past 6 months\n* Adults unable to consent","22 Years",{"count":98,"type":23},[26],"Declines in iron status are common in those with obesity and may be due to obesity-related chronic inflammation; however, the effects of reducing inflammation following diet-induced weight loss on iron metabolism are poorly understood. Low environmental oxygen exposure increases dietary iron absorption and availability to supply iron for erythropoiesis but has not yet been tested in the context of weight loss. This study is designed to investigate diet-induced weight loss (inflammation reduction) and overnight low oxygen exposure (erythropoiesis stimulating agent) as strategies to improve dietary iron absorption in obesity.",[30],[570,571,572,573,574,575,576],"Body weight","Normobaric hypoxia","Negative energy balance","Energy intake","Energy expenditure","Iron absorption","Iron metabolism","2026-04-14",{"date":523,"type":44},{"date":580,"type":44},"2025-04-21",{"date":202,"type":23},{"name":173,"class":51},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":214,"sex":18,"minAge":591,"maxAge":4,"enrollmentInfo":592,"targetDuration":593,"studyType":64,"phases":4,"briefSummary":594,"conditions":595,"keywords":597,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":52},"100634444","obese-hfpef-towards-preventing-obesity-related-hfpef-100634444","NCT07539766","OBESE-HFpEF: Towards Preventing Obesity Related HFpEF","OBESE-HFpEF: Prevalence and Mediators of Heart Failure (Preserved Ejection Fraction) in the Dutch Obesity Clinic South - Towards Preventing Obesity Related HFpEF''","OBESE-HFpEF","Inclusion Criteria:\n\n* Age ≥ 35 years\n* Eligible for surgical treatment for obesity, according to the Dutch guideline, i.e. a BMI ≥ 40 kg\u002Fm2 or a BMI ≥ 35 kg\u002Fm2 with one or more comorbidities associated with obesity. (23)\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* A BMI \\>60 kg\u002Fm2\n* Inability of undergoing metabolic bariatric surgery safely.\n* Inability to undergo the study measurement\u002Ftests.\n* Not proficient in the Dutch language\n* A medical history of a reduced LVEF at any time, history of severe cardiac valve defects or severe congenital cardiac defects.\n* A medical history of previous metabolic bariatric surgery.","35 Years",{"count":182,"type":23},"2 Years","Obesity, severe overweight, is a growing problem worldwide and increases the risk of heart failure, especially a type called heart failure with preserved ejection fraction (HFpEF).\n\nIn HFpEF, the heart becomes stiffer. This makes it harder for the heart to fill with blood, which can lead to shortness of breath during physical activity.\n\nIn the Netherlands, 15% of the population has obesity. In South Limburg, this is even higher at 19%. Among people with HFpEF, obesity is much more common: about 50% of these patients have obesity.\n\nLife expectancy in people with HFpEF is poor, and current treatment mainly focuses on reducing symptoms. Early recognition and treatment of risk factors, such as obesity, are therefore very important.\n\nThis study includes about 250 people with obesity. Using a heart ultrasound and tests of blood and fat tissue, we will look for early signs of HFpEF and study the effects of weight loss. The measurements will be repeated after 1 and 2 years.\n\nThe goal of this study is to better understand how obesity contributes to HFpEF and how weight loss affects the heart. This research may help improve future treatments for patients with HFpEF.",[596,30,417],"Heart Failure and Preserved Ejection Fraction",[74,598,599,600],"Heart Failure with preserved ejection fraction","Metabolic Bariatric Surgery","Prospective","2026-04-13",{"date":316,"type":44},{"date":604,"type":44},"2025-01-01",{"date":606,"type":23},"2029-01-01",{"name":608,"class":51},"Zuyderland Medisch Centrum",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":214,"sex":18,"minAge":616,"maxAge":617,"enrollmentInfo":618,"targetDuration":4,"studyType":24,"phases":620,"briefSummary":621,"conditions":622,"keywords":623,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":639},"100631805","ai-informed-peer-mentoring-behavioral-intervention-for-obesity-and-cardiovascular-disease-primary-prevention-in-youth-100631805","NCT07505459","AI-INFORMED PEER-MENTORING BEHAVIORAL INTERVENTION FOR OBESITY AND CARDIOVASCULAR DISEASE PRIMARY PREVENTION IN YOUTH","PeerMentorOBCV","Inclusion Criteria:\n\nHealthy individuals aged 12-25 yrs -\n\nExclusion Criteria:\n\nObesity Severe cognitive and communication deficits\n\n\\-","12 Years","25 Years",{"count":619,"type":23},840,[26],"The goal of this clinical trial is to learn if an AI-based peer-mentoring works to prevent obesity in adolescents and young adults. The main questions it aims to answer are:\n\nDoes the AI-based peer-mentoring improve dietary habits and increase physical activity in healthy individuals 12-25 yrs old? Does the AI-based peer-mentoring reduces the risk of obesity?\n\nResearchers will compare the AI-based behavioral peer-mentoring intervention to traditional peer-mentoring and to health education intervention to see if AI-based peer-mentoring is more effective.\n\nParticipants will:\n\nFollow either a structured AI-based peer-mentoring program or a traditional peer-mentoring program or health education sessions focusing on diet and physical activity They will be evaluated at baseline, at 6 months and at 12 months",[30],[624,74,625,626,627,628,629,630],"Peer-mentoring","Behavioral change","Nutrition","Physical activity","Youth","Digital health","prevention","2026-04-09",{"date":577,"type":44},{"date":634,"type":23},"2027-09-01",{"date":636,"type":23},"2028-12-30",{"name":638,"class":51},"Aikaterini Karaivazoglou",3,{"id":641,"slug":642,"hasResults":12,"nctId":643,"briefTitle":644,"officialTitle":645,"acronym":646,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":18,"minAge":617,"maxAge":20,"enrollmentInfo":648,"targetDuration":4,"studyType":24,"phases":650,"briefSummary":651,"conditions":652,"keywords":653,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":639},"100613585","impact-of-a-pro-diversity-gut-microbiota-diet-after-a-bariatric-surgery-on-gut-microbiota-eating-behaviour-and-sensory-function-100613585","NCT07268508","Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory Function","Randomised Controlled Trial Evaluating the Impact of a Pro-diversity Gut Microbiota Diet on Gut Microbiota, Eating Behaviour and Sensory Function in Patients Who Have Undergone Bariatric Surgery","BariaGut Taste","Inclusion Criteria:\n\n* Between 25 and 65 years old\n* Undergoing either sleeve gastrectomy or Roux-en-Y gastric bypass\n* With grade 3 obesity (BMI≥40 kg\u002Fm²) or with BMI≥35 kg\u002Fm² and at least one comorbidity likely to be improved after surgery, with the exception of type 2 diabetes\n* Signed consent form\n* Living less than an hour and 30 minutes from the hospital\n* Presence of effective and stable contraception for women of childbearing potential\n\nExclusion Criteria:\n\n* Type 2 diabetes\n* Presence of a contraindication to bariatric surgery\n* Presence of gastrointestinal pathologies with an inflammatory component, known gastroparesis, total gastrectomy, colectomy, exocrine pancreatic insufficiency, known endocrine pathologies inducing hyperglycaemia (uncontrolled dysthyroidism, acromegaly, hypercorticism, etc.), severe chronic renal insufficiency (\\\u003C 30mL\u002Fmin), or hepatocellular insufficiency\n* Claustrophobic\n* Pregnant or breastfeeding women\n* Taking an obesity treatment 3 months before surgery\n* Taking a corticoids, immunosuppression, anabolizing, or growing hormones, antibody treatments less than 3 months before inclusion\n* Daily taking of laxatives or drugs that can strongly interfere with the composition of the intestinal microbiota. If taken sporadically, the patient can be included at a distance (3 weeks) from the laxatives taken.\n* Specific diets (vegetarian, vegan or without gluten)\n* No French speaker\n* Already included in other study\n* Donated blood in the last two months\n* Without freezer access\n* With allergy or intolerance to food propose in ad libitum buffet",{"count":649,"type":23},60,[26],"Bariatric surgery is the most effective treatment for long-term weight loss and reducing obesity-related health risks. It alters the gastrointestinal tract as well as metabolic and hormonal functions, influencing eating behaviour. However, weight loss outcomes and long-term maintenance vary between patients, likely due to changes in the gut microbiota. Dietary recommendations aimed at improving microbiota diversity could help support sustained weight loss after surgery.\n\nThe BariaGut Taste study aims to compare two dietary approaches following bariatric surgery: nutritional counselling promoting gut microbiota diversity versus standard nutritional counselling. One year after surgery, the study will evaluate differences in microbiota diversity, changes in food preferences and eating behaviours, sensory profiles (taste, smell), levels of digestive and gut hormones fasting, before and after eating, cardiometabolic parameters, mental health, physical activity, and more, to better understand Bariatric surgery is the most effective treatment for long-term weight loss and reducing obesity-related health risks. It alters the gastrointestinal tract as well as metabolic and hormonal functions, influencing eating behaviour. However, weight loss outcomes and long-term maintenance vary between patients, likely due to changes in the gut microbiota. Dietary recommendations aimed at improving microbiota diversity could help support sustained weight loss after surgery.\n\nThe BariaGut Taste study aims to compare two dietary approaches following bariatric surgery: nutritional counselling promoting gut microbiota diversity versus standard nutritional counselling. One year after surgery, the study will evaluate differences in microbiota diversity, changes in food preferences and eating behaviours, sensory profiles (taste, smell), levels of digestive and gut hormones fasting, before and after eating, cardiometabolic parameters, mental health, physical activity, and more, to better understand the mechanisms that may explain variations in response to bariatric surgery.\n\nThe BariaGut Taste study is a prospective, randomized, controlled trial with two parallel groups, involving non-diabetic patients aged 25 to 65 y undergoing either sleeve gastrectomy or Roux-en-Y gastric bypass. The trial will be conducted at the digestive surgery department of Edouard Herriot Hospital, the endocrinology-diabetes-nutrition department of Lyon Sud Hospital Center, and the Human Nutrition Research Center Rhône-Alpes. 60 participants are expected to be recruited, with 30 in each arm.\n\nParticipants will be enrolled before surgery during a routine care visit with the surgeon. They will then undergo a metabolic assessment visit conducted exclusively for research purposes. This visit will allow to collect baseline data on primary outcomes via blood, expired air, and stool samples, anthropometric measurements, indirect calorimetry, a battery of questionnaires (TFEQ-21, DEBQ, PHQ-9, SF36, GSES, PANAS, ESUL, BES, DERS, GAD-7, IPAQ, BAQ, GSRS, sensory alterations, Bristol and Likert scales, and FNS), computerized food preference tests (LFPQ), and a standardized, video-recorded ad libitum buffet.\n\nParticipants will be followed up at 3, 6, and 12 months after surgery through visits combining clinical care and research assessments. The dietary interventions specific to each group will be provided since the 3-month visit. The assessments conducted before surgery will be repeated at 6 and 12 months, also integrating clinical care objectives.\n\nAdditional blood, stool, and adipose tissue samples collected during surgery will be stored to create a biobank.",[30,188],[654,655,656,657,658],"Bariatric surgery","gut microbiota","sensory alteration","food preferences","weight loss maintenance","2026-04-02",{"date":661,"type":44},"2026-04-03",{"date":663,"type":44},"2025-11-05",{"date":665,"type":23},"2029-04-05",{"name":667,"class":51},"Hospices Civils de Lyon",{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":214,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":674,"targetDuration":4,"studyType":24,"phases":676,"briefSummary":677,"conditions":678,"keywords":679,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":682,"lastUpdatePostDateStruct":683,"startDateStruct":685,"completionDateStruct":687,"leadSponsor":688,"locationsCount":52},"100615421","examining-valence-based-effects-in-self-monitoring-feedback-messages-100615421","NCT07292389","Examining Valence-based Effects in Self-Monitoring Feedback Messages","Examining Valence-based Effects in Self-monitoring Feedback Messages, in the Development of a Novel Semi-automated Self-monitoring Feedback System for Obesity Treatment",{"count":675,"type":23},127,[26],"The purpose of this research study is to learn how to identify the most effective ways to provide weekly feedback on participants' progress toward intervention goals during a weight loss program.",[186,30],[247,248,249,250,251,253,254,255,256,257,680,681],"behavior change","self-monitor activity","2026-03-30",{"date":684,"type":44},"2026-03-31",{"date":686,"type":44},"2026-03-23",{"date":529,"type":23},{"name":689,"class":51},"University of Virginia",{"id":691,"slug":692,"hasResults":12,"nctId":693,"briefTitle":694,"officialTitle":695,"acronym":696,"eligibilityCriteria":697,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":698,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":700,"conditions":701,"keywords":702,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":707,"lastUpdatePostDateStruct":708,"startDateStruct":709,"completionDateStruct":711,"leadSponsor":712,"locationsCount":714},"100631706","real-world-effectiveness-and-dosing-patterns-of-tirzepatide-in-people-with-obesity-100631706","NCT07504172","Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity","Real-world Effectiveness and Dosing Patterns of Tirzepatide: A Multicentre Retrospective Observational Study in the Netherlands","TIRZ-DOSE-NL","Inclusion Criteria:\n\n* Adults (age ≥18 years old)\n* A BMI of ≥ 30 kg\u002Fm2 or a BMI ≥ 27 kg\u002Fm2 with at least one obesity complication (e.g., hypertension, dyslipidaemia)\n\nExclusion Criteria:\n\n* Pregnant women or pregnancy during treatment\n* Previously treated for obesity (with pharmacotherapy, endoscopic treatment or metabolic-bariatric surgery)\n* Patients with diabetes",{"count":699,"type":23},1700,"Tirzepatide is one of the new medications for the treatment of obesity. In clinical research people treated with Tirzepatide have weight loss up to 21%. But there is only a little bit of research showing the effect of Tirzepatide in clinical practice.\n\nIn this retrospective observational study the investigators will evaluate the effectiveness of tirzepatide in routine clinical practice among adults with obesity in the Netherlands.The main questions it aims to answer are:\n\n* How much weight do patients lose after six months of treatment with tirzepatide combined with lifestyle coaching?\n* How is the medication dosed in daily practice? Researchers will use data from electronic health records of patients in multiple outpatient locations of the Dutch Obesity Clinic (NOK, Nederlandse Obesitas Kliniek).",[67,30],[74,703,424,704,705,706],"Weightloss","Adults","Body composition","Dose escalation","2026-03-25",{"date":684,"type":44},{"date":710,"type":23},"2026-04-01",{"date":230,"type":23},{"name":713,"class":51},"Radboud University Medical Center",10,{"id":716,"slug":717,"hasResults":12,"nctId":718,"briefTitle":719,"officialTitle":720,"acronym":4,"eligibilityCriteria":721,"healthyVolunteers":12,"sex":18,"minAge":61,"maxAge":20,"enrollmentInfo":722,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":724,"conditions":725,"keywords":730,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":735,"lastUpdatePostDateStruct":736,"startDateStruct":738,"completionDateStruct":740,"leadSponsor":742,"locationsCount":52},"100617250","predicting-difficult-intubation-in-bariatric-surgery-comparison-of-el-ganzouri-risk-index-and-airway-ultrasound-100617250","NCT07316179","Predicting Difficult Intubation in Bariatric Surgery: Comparison of El Ganzouri Risk Index and Airway Ultrasound","A Prospective Observational Study Comparing the El Ganzouri Risk Index and Airway Ultrasonography in Predicting Difficult Intubation in Patients Undergoing Bariatric Surgery","Inclusion Criteria:\n\n* Adult patients aged 18 to 65 years.\n* ASA physical status classification II or III.\n* Scheduled to undergo elective bariatric surgery under general anesthesia.\n* Patients who voluntarily agree to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients younger than 18 years or older than 65 years\n* Presence of upper airway anatomical pathology\n* History of tracheal or thyroid surgery.\n* History of radiotherapy to the head and neck region.\n* Cervical spine anomalies.\n\nIndividuals unwilling to participate in the study.",{"count":723,"type":23},52,"This study is designed as a prospective observational study and will be conducted at the Health Sciences University Antalya Training and Research Hospital. Adult patients scheduled to undergo bariatric surgery will be included.\n\nThe aim of this study is to compare the El Ganzouri Risk Index (EGRI) and airway ultrasonography (USG) parameters in predicting difficult intubation and to evaluate their relationship with the Cormack-Lehane (CL) score obtained during direct laryngoscopy.\n\nBefore surgery, each participant will be evaluated using both the EGRI scoring system and airway USG. During general anesthesia, tracheal intubation will be performed using direct laryngoscopy, and data including the CL score, intubation time, number of attempts, and the need for videolaryngoscopy will be recorded based on the anesthesiologist's observations.\n\nThe collected data will be analyzed by classifying participants according to the presence or absence of difficult intubation, and statistical comparisons will be performed between EGRI scores and airway ultrasonography parameters. The results of this study may contribute to improved preoperative airway assessment and enhanced patient safety in bariatric surgery.",[186,726,30,727,728,729],"Obesity Difficult Airway Airway Management","Difficult Airway","Difficult Intubation in Obesity","Difficult Laryngoscopy",[731,732,74,733,734],"El Ganzouri Risk Index","Difficult airway","Airway Ultrasonography","Airway Management","2026-03-06",{"date":737,"type":44},"2026-03-09",{"date":739,"type":44},"2025-12-25",{"date":741,"type":23},"2026-07-28",{"name":743,"class":744},"Antalya Training and Research Hospital","OTHER_GOV"]